InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (2 ops.)
Insider track record
OtherDisclosed buys
2
Disclosed sells
2
T+90 hit rate
100%
T+90 mean return
+11.2%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Dexcel Pharma Technologies Ltd.. Officer active across 2 companies, notably Protalix BioTherapeutics, Inc.. In total, 4 reports have been recorded. Split: 2 buys · 2 sells. Total volume traded: €20.3m. History available since 2 June 2021. The latest transaction was filed on 10 November 2022 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations4 total
4,000,000 shares@ US$5.0099.4% of flowCommon SharesSEC:0001104659-22-117847:0
Ideal exit: 7 Aug 2023 (T+270)
31,685 shares@ US$3.82890.0005% mcap100.0% of flowCommon SharesSEC:0001104659-22-049930:0
Ideal exit: 17 Jan 2023 (T+270)
61,211 shares@ US$2.55760.080% mcap50.0% of flowCommon StockSEC:0001104659-21-076488:0
61,211 shares@ US$2.557650.0% of flowCommon StockSEC:0001104659-21-076488
4 of 4 declarations
